I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Anti-VEGF Injections for Retinal Disease
Understanding Anti-VEGF Therapy
Anti-VEGF therapy targets a specific protein that plays a central role in several sight-threatening retinal diseases. Understanding how the treatment works helps patients feel more confident about starting and staying with therapy.
VEGF is a protein the body uses to help form new blood vessels when tissues need repair or oxygen. In healthy eyes, this is a tightly controlled process. In certain retinal diseases, however, the eye produces too much VEGF. This excess triggers the growth of abnormal, fragile blood vessels beneath or within the retina. These vessels leak blood and fluid, damaging the light-sensitive cells responsible for sharp central vision.
Anti-VEGF medications are biologic drugs, meaning they are manufactured from living cells and are designed to target a specific protein. When injected into the vitreous (the gel-filled interior of the eye), these drugs bind to VEGF molecules and prevent them from attaching to the cells that line blood vessels. This action reduces leakage from abnormal vessels, prevents new abnormal vessels from forming, and can cause existing ones to shrink. Over time, this process allows the retina to stabilize and can lead to measurable improvements in vision.
Anti-VEGF therapy is used for several retinal conditions in which excess VEGF plays a central role. The most commonly treated conditions include:
- Wet age-related macular degeneration (wet AMD), in which abnormal blood vessels grow beneath the macula, the region of the retina responsible for central, detailed vision
- Diabetic macular edema (DME), which involves fluid swelling in the central retina caused by diabetes-related vascular damage
- Diabetic retinopathy, in which diabetes weakens and damages blood vessels throughout the retina
- Retinal vein occlusions (RVO), which occur when a vein draining the retina becomes blocked, causing fluid accumulation and vision loss
Before anti-VEGF medications became available, treatment options for conditions like wet AMD were limited. Laser treatments could slow vision loss in some patients but rarely restored it. The introduction of anti-VEGF therapy changed the standard of care entirely. For the first time, retina specialists could stop the progression of these diseases and help many patients recover some of the vision they had lost. Today, anti-VEGF injections are the primary treatment for multiple sight-threatening retinal conditions.
Available Anti-VEGF Medications
Several anti-VEGF medications are currently used to treat retinal disease. Our physicians select the medication that best fits each patient's diagnosis, treatment history, and individual response. All of these medications are given by injection into the eye.
Lucentis (ranibizumab) was the first anti-VEGF drug approved specifically for use in the eye. It is FDA-approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions. Lucentis is typically given every four weeks, though some patients may be managed on an extended interval once their condition is well controlled. Biosimilar versions of ranibizumab, including Byooviz and Cimerli, are also available and provide comparable treatment options.
Eylea (aflibercept) was approved in 2011 and has become one of the most widely used anti-VEGF agents in retinal care. It is approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions. Eylea is typically given every four to eight weeks after an initial series of monthly loading doses. Eylea HD is a higher-concentration formulation approved for wet AMD and DME. Its higher dose may allow longer intervals between injections after the loading phase, potentially reducing the number of office visits needed each year.
Avastin (bevacizumab) was originally developed and FDA-approved to treat certain cancers. It is used off-label for retinal conditions, meaning it does not carry a specific FDA approval for eye use. Despite this, large clinical trials have demonstrated its effectiveness for wet AMD and other retinal diseases, and it has a well-established track record in the retina specialty. It is typically administered every four to six weeks.
Vabysmo (faricimab) was approved in 2022 and works differently from other anti-VEGF medications. It is a bispecific antibody, meaning it blocks two proteins involved in retinal disease: VEGF and angiopoietin-2 (Ang-2). Angiopoietin-2 contributes to blood vessel instability and leakage, so blocking both proteins together may provide more complete disease control. Vabysmo is approved for wet AMD and DME. Some patients may be able to go up to sixteen weeks between injections, which can meaningfully reduce the number of visits needed over the course of a year.
Beovu (brolucizumab) is approved for wet AMD and can be administered every eight to twelve weeks after initial loading doses. It carries a known risk of retinal vasculitis, which is inflammation of the blood vessels in the retina, and retinal artery occlusion, a blockage of blood flow within the retina. Because of these risks, Beovu is generally considered for patients who have not responded adequately to other anti-VEGF options. Patients receiving this medication are monitored closely for signs of inflammation throughout their course of treatment.
Who May Need Anti-VEGF Treatment
Several factors increase the likelihood of developing a retinal condition that may require anti-VEGF therapy. Knowing your personal risk profile can help you seek evaluation early, when treatment is typically most effective.
Advanced age is the primary risk factor for wet AMD, the most common condition treated with anti-VEGF injections. Risk increases significantly after age 60. A family history of AMD also raises a person's likelihood of developing the condition, as genetics play a meaningful role. Anyone with a close relative diagnosed with AMD should discuss appropriate screening with their eye care provider.
Diabetes is the leading cause of diabetic retinopathy and diabetic macular edema. The longer a person has lived with diabetes and the less well-managed their blood sugar has been, the greater their risk of developing diabetic eye disease. High blood pressure and cardiovascular disease also contribute to retinal vascular problems, including retinal vein occlusions. Managing these systemic conditions is an important part of protecting long-term retinal health.
Smoking is one of the most significant modifiable risk factors for AMD. Research has shown that smoking can more than double the risk of developing the disease. Quitting at any age can help reduce that elevated risk. A diet rich in leafy greens, fish, and antioxidants may support retinal health, though dietary choices alone do not replace the need for treatment once a retinal condition has developed.
Recognizing Symptoms That Need Evaluation
Retinal conditions can develop gradually or appear suddenly. Knowing what to look for helps ensure care is sought at the earliest possible stage, when outcomes tend to be best.
Many retinal conditions develop slowly over time. Early signs may include blurred central vision, difficulty reading, a need for brighter light to see clearly, or colors appearing less vivid than usual. Straight lines that appear wavy or bent are a symptom called metamorphopsia, and this can be an early warning sign of macular disease. These changes are often subtle at first and may affect only one eye, making them easy to overlook or attribute to aging. Any persistent change in your vision deserves evaluation.
Some retinal conditions produce symptoms that appear rapidly and require immediate attention. A sudden increase in floaters (spots or threads drifting across your visual field), flashes of light, a curtain or shadow spreading over part of your vision, or sudden vision loss in one eye are all potential warning signs of a serious retinal emergency. If you experience any of these symptoms, contact a retina specialist or go to an emergency room right away. Delaying care in these situations can result in severe and permanent vision loss.
Diagnosing Retinal Conditions
Before recommending anti-VEGF therapy, our specialists use a combination of clinical examination and advanced imaging to evaluate the retina thoroughly. Accurate diagnosis guides every treatment decision we make.
A retina specialist begins with a comprehensive dilated eye exam. Drops are used to widen the pupil, allowing a detailed view of the retina. This exam can reveal abnormal blood vessels, fluid buildup, bleeding, and structural changes within the retina. Visual acuity testing is also performed to measure how clearly you see at different distances.
Optical coherence tomography, known as OCT, is a noninvasive imaging test that produces detailed cross-sectional images of the retina. It can detect fluid within or beneath the retinal layers, measure retinal thickness, and identify microscopic structural changes that may not be visible during a standard exam. OCT is one of the most valuable tools used both to confirm a diagnosis and to monitor how the retina responds to treatment over time.
Fluorescein angiography uses a special dye to map blood flow through the retina. The dye is injected into a vein in the arm and travels to the eye within seconds, where a camera captures rapid images as it passes through the retinal blood vessels. This test identifies leaking vessels, areas of poor circulation, and abnormal new vessel growth. It provides detailed information that helps our physicians plan the most appropriate treatment approach for each patient.
The Injection Process
The thought of an eye injection can feel intimidating, but most patients find the actual procedure much easier than they anticipated. Understanding each stage of the process helps reduce anxiety before the appointment.
The eye and surrounding area are thoroughly cleaned with an antiseptic solution to minimize the risk of infection. Numbing drops or a small amount of local anesthetic are applied to reduce discomfort. A small clip called a lid speculum is gently placed to keep the eyelids open so there is no need to worry about blinking during the procedure. This preparation typically takes only a few minutes.
The injection is administered using a very fine needle inserted through the sclera (the white outer wall of the eye) and into the vitreous cavity, the gel-filled interior space of the eye. The medication is delivered in a very small volume. Most patients describe feeling a brief sense of pressure rather than sharp pain. The injection itself takes only a few seconds. The entire office visit, including preparation and a brief check afterward, typically takes about thirty minutes.
Immediately following the injection, you may notice some floaters, mild redness on the white of the eye, or a gritty or slightly sore feeling. These are expected and usually resolve within a few days. Your physician may check your eye pressure before you leave the office. Most patients are able to return to their normal daily activities the same day, though you should follow any specific post-procedure instructions provided by our team.
Treatment frequency depends on the medication used and how your retina responds. Most patients begin with monthly loading doses, typically three to four injections given four weeks apart. After this initial phase, the time between injections may be gradually extended using a treat-and-extend approach, where your physician lengthens the interval as long as the retina remains stable. With newer agents such as Vabysmo and Eylea HD, some patients can go three to four months between visits. Individual schedules vary and are adjusted continuously based on examination findings and imaging.
What to Expect from Treatment
Understanding realistic expectations before starting therapy helps patients stay committed to their treatment plan. Outcomes depend on the condition being treated, how early treatment begins, and how consistently appointments are kept.
Anti-VEGF treatment improves vision in a meaningful portion of patients and stabilizes vision in the large majority of those treated for wet AMD and related retinal diseases. The primary goal of treatment is to preserve the vision you currently have and, when possible, recover some of what may have been lost. Not every patient will experience measurable improvement, but most patients who maintain a consistent treatment schedule can expect their condition to stabilize rather than worsen.
Anti-VEGF therapy works best when it is sustained over time. Skipping or delaying injections can allow the underlying disease to become active again, leading to new fluid leakage and further retinal damage. Some of that vision loss may not be reversible. Keeping all scheduled appointments is one of the most important steps you can take to protect your sight. If scheduling challenges arise, please let our team know so we can work with you to find a solution.
Anti-VEGF injections have a well-established safety record developed over many years and millions of injections. Common short-term effects include mild redness, temporary floaters, and a gritty or sore sensation, all of which typically resolve quickly on their own. Serious complications are uncommon. Endophthalmitis, a severe infection inside the eye, is rare but represents a medical emergency. If you develop intense eye pain, a sudden drop in vision, markedly increased redness, or any discharge from the eye within days of an injection, contact our office immediately or go to an emergency room without delay. Early treatment of this complication is critical.
Living with Long-Term Anti-VEGF Treatment
For many patients, anti-VEGF therapy becomes an ongoing part of life for years. Building practical habits and emotional support around treatment can make the process more manageable and help protect vision over the long term.
Because anti-VEGF therapy continues for extended periods in most cases, staying organized with your schedule is worthwhile. Using a calendar, setting phone reminders, or asking a trusted family member or friend to help track appointments can prevent unintentional gaps in treatment. Some patients find it helpful to pair injection visits with other regular errands or medical appointments to make the routine easier to maintain.
Between appointments, an Amsler grid is a practical tool for monitoring your central vision. This simple chart consists of a grid of straight lines with a central dot. By looking at the grid with one eye covered at a time, you can detect new areas of distortion, blurriness, or missing patches in your visual field. These changes may indicate the disease is becoming more active. Do not wait for your next scheduled visit if you notice something new. Contact our office promptly so we can evaluate you sooner.
Managing a chronic eye condition and attending regular injection appointments can be emotionally demanding. It is completely normal to feel anxious before procedures or worried about your future vision. Talking openly with family members, friends, or a counselor can make a meaningful difference. Low vision rehabilitation services and patient support groups are available for those who have experienced significant vision changes and would benefit from additional guidance and community.
Frequently Asked Questions
These questions address common concerns we hear from patients when they are starting or continuing anti-VEGF therapy.
Most patients are surprised by how manageable the experience is. Numbing drops or local anesthetic are applied before the injection so the needle entry causes minimal discomfort. The most common description patients give is a brief sense of pressure rather than pain. Mild soreness or irritation may follow and typically resolves within a day or two. If significant pain develops or worsens after returning home, contact our office rather than waiting for your next appointment.
For most retinal conditions treated with anti-VEGF therapy, treatment is ongoing rather than time-limited. Wet AMD, diabetic eye disease, and retinal vein occlusions are chronic conditions, and disease activity can return if injections are stopped. As your retina stabilizes, your physician may gradually extend the time between treatments. The goal over time is always to identify the least frequent dosing schedule that still keeps your retina protected. This is reassessed at every visit based on how your eye looks on imaging and examination.
Large, rigorous clinical trials have found Avastin to be effective for wet AMD and other retinal diseases even though it is used off-label for eye conditions. The decision between Avastin and a drug with a direct ophthalmic indication depends on individual clinical factors, insurance coverage, and your physician's assessment of your specific situation. All anti-VEGF agents used in our practice have documented evidence supporting their effectiveness. Your physician will explain the reasoning behind any medication recommendation.
Missing one appointment does not mean your treatment has failed, but a gap in therapy creates a window during which VEGF activity can increase and new fluid can accumulate in the retina. The longer the gap, the greater the potential for disease reactivation and vision change. If you need to reschedule, contact our office as soon as possible so we can minimize the delay and get you back on track. Communicating early always produces better outcomes than waiting in silence.
For most patients with wet AMD, DME, or retinal vein occlusions, anti-VEGF injections remain the most effective treatment currently available. In selected cases, laser photocoagulation or corticosteroid implants may be used alongside or instead of anti-VEGF therapy depending on the clinical picture. Research into longer-lasting options, including sustained-release implants and gene therapy approaches, is actively ongoing. Your retina specialist can explain which alternatives may apply to your specific diagnosis and prior treatment history.
Retinal Expertise at New England Retina Associates
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons bring specialized expertise to the diagnosis and treatment of retinal disease across all four of our Connecticut offices. We welcome referred patients, self-referred patients, and those with urgent retinal concerns, and we are committed to providing care that is both expert and genuinely patient-centered. If you or someone you care about has been diagnosed with a retinal condition or is experiencing changes in vision, we encourage you to contact us so we can help you take the next step toward protecting your sight.
30 Years of Care & Commitment
